Physician profile
Anna Wong
NPI 1194037481
$13,938.23
in general payments reported to CMS, 2019-2025
31 companies · $712 in 2025
The $712 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,128 · 2022: $4,566 · 2023: $3,759 · 2024: $1,773 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,244.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,400.44 | 2021-2025 | |
| Gilead Sciences, INC. | $1,419.36 | 2021-2025 | Vemlidy |
| Astrazeneca Pharmaceuticals LP | $1,364.59 | 2021-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $1,008.96 | 2021-2025 | |
| Amgen INC. | $847.98 | 2021-2023 | Otezla, Evenity, Prolia |
| Glaxosmithkline, LLC. | $807.37 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $710.06 | 2021-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $708.49 | 2021-2023 | Nexletol |
| Lilly USA, LLC | $659.88 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.63 | 2021-2023 | Jardiance |
| Novo Nordisk INC | $372.87 | 2021-2023 | Rybelsus, Ozempic |
| Nestle Healthcare Nutrition INC. | $352.57 | 2021-2023 | |
| Redhill Biopharma INC. | $343.75 | 2022-2023 | Aemcolo, Talicia, Movantik |
| Sun Pharmaceutical Industries INC. | $292.20 | 2022-2023 | Cequa |
| Amarin Pharma, INC. | $270.57 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $256.75 | 2022-2024 | Linzess |
| Biohaven Pharmaceuticals, INC. | $249.95 | 2021 | |
| Pfizer INC. | $231.09 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $183.79 | 2024 | Voquezna |
| Dexcom, INC. | $179.05 | 2022-2023 | Dexcom G6 Transmitter |
| Alkermes, INC. | $137.13 | 2022 | |
| Eisai INC. | $125.00 | 2021 | |
| Mannkind Corporation | $101.15 | 2022-2024 | Afrezza |
| Novartis Pharmaceuticals Corporation | $64.58 | 2023-2024 | |
| Ibsa Pharma INC. | $51.59 | 2023 | Tirosint, Licart |
| E.R. Squibb & Sons, L.L.C. | $38.74 | 2021-2022 | |
| Vivus LLC | $33.27 | 2023 | Pancreaze |
| Exact Sciences Corporation | $24.91 | 2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $20.54 | 2023 | Yupelri |
| Horizon Therapeutics Plc | $19.29 | 2022 | |
| Scilex Pharmaceuticals INC. | $15.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.